Drug intelligence / Profile preview

XYL-2004

Development stage: Preclinical
Lead developer: Xylo Bio
Modality: Small Molecules

Overview

XYL-2004 is a small molecule neurotherapeutic being developed by Psylo (doing business as Xylo Bio). It is designed as a dual modulator of the 5-HT2A and 5-HT2C serotonin receptors. The program focuses on leveraging neuroplasticity for the treatment of chronic pain and various mood disorders. Currently in the preclinical or IND-enabling stage, XYL-2004 is part of a broader pipeline of serotonin-targeting compounds intended to provide therapeutic benefits with potentially improved profiles compared to traditional psychedelics.

Targets

HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on XYL-2004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XYL-2004.

Explore the full profile